Quarterly report pursuant to Section 13 or 15(d)

Stock Based Compensation Arrangements

v3.7.0.1
Stock Based Compensation Arrangements
6 Months Ended
Apr. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock Based Compensation Arrangements

8. STOCK BASED COMPENSATION ARRANGEMENTS

 

Stock-based compensation expense during the three months ended April 30, 2017 and 2016 amounted to approximately $4.2 million and $446,000 respectively. Stock-based compensation expense during the six months ended April 30, 2017 and 2016 amounted to approximately $8.6 million and $993,000 respectively. Stock-based compensation expense is recorded in general and administrative expenses in the accompanying consolidated statements of operations.

 

On February 8, 2017, the Board appointed Steve Gorlin as a Class II director with a term expiring in 2019 and Dr. Jon Mogford as a Class III director with a term expiring in 2017 to fill vacancies created upon the resignations of Messrs. Brauser and Honig. In addition, Mr. Gorlin was appointed as a member of each of the Board’s Audit, Compensation and Nominating and Corporate Governance Committees. Each of Mr. Gorlin and Dr. Mogford are deemed an “independent” director as such term is defined by the rules of The NASDAQ Stock Market LLC. There are no family relationships between either of Mr. Gorlin and Dr. Mogford and any of our other officers and directors. Mr. Gorlin and Dr. Mogford were each granted (i) an option to purchase up to 50,000 shares of the Company’s common stock at an exercise price equal to $4.72 per share (the “Options”) which Options will vest in 24 equal monthly installments commencing on the one month anniversary of the grant date and (ii) a restricted stock award of 50,000 shares of common stock that will vest in 24 equal monthly installments commencing on the one month anniversary of the grant date (the “RSUs”). The Options and the RSUs were granted pursuant to the Company’s 2017 Equity Incentive Plan (the “2017 Plan”). The 2017 Plan, the vesting and the exercise of the Options and the vesting of the RSUs are subject to stockholder approval.

 

A summary of the Company’s employee stock option activity in the six months ended April 30, 2017 is presented below:

 

   

Number of

shares

   

Weighted-Average

Exercise Price

 
Outstanding - October 31, 2016     383,210     $ 5.74  
Granted     2,715,000     $ 3.49  
Exercised     (121,698 )   $ 4.83  
Outstanding - April 30, 2017     2,976,512     $ 3.72  
Options exercisable - April 30, 2017     767,342     $ 4.19  
Weighted-average fair value of options granted during the period           $ 2.37  

 

A summary of the Company’s non-employee stock option activity in the six months ended April 30, 2017 is presented below:

 

   

Number of

shares

   

Weighted-Average

Exercise Price

 
Outstanding - October 31, 2016     -     $ -  
Granted     52,000     $ 4.71  
Outstanding - April 30, 2017     52,000     $ 4.71  
Options exercisable - April 30, 2017     4,333     $ 4.71  

 

The value of employee and non-employee stock option grants is amortized over the vesting period of, generally, one to three years. As of April 30, 2017, there was approximately $6.3 million of unrecognized compensation cost related to non-vested employee and non-employee stock option awards, which is expected to be recognized over a remaining weighted-average vesting period of 0.8 years.

 

The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions for the six months ended April 30, 2017:

 

Risk free annual interest rate     1.78-2.28 %
Expected volatility     71.65-86.34 %
Expected life     5.04-6.00  
Assumed dividends   None  

 

A summary of the Company’s restricted stock activity in the six months ended April 30, 2017 is presented below:

 

   

Number of

shares

    Weighted-Average Grant-Date Fair Value  
Unvested - October 31, 2016     274,829     $ 6.00  
Granted     1,031,000     $ 4.56  
Vested     (925,488 )   $ 4.00  
Unvested - April 30, 2017     380,341     $ 6.97  

 

During the six months ended April 30, 2017, the Company granted 1,031,000 restricted shares to employees and non-employees.

 

The weighted-average fair value of restricted shares granted during the six months ended April 30, 2017 was $4.56. The total fair value of restricted stock granted during the six months ended April 30, 2017 was approximately $4.7 million.

 

The value of restricted stock grants is measured based on its fair value on the date of grant and amortized over the vesting period of, generally, six months to three years. As of April 30, 2017, there was approximately $2.4 million of unrecognized compensation cost related to unvested restricted stock awards, which is expected to be recognized over a remaining weighted-average vesting period of 0.7 years.